Previous Close | 1.4500 |
Open | 1.4100 |
Bid | 1.3200 x 800 |
Ask | 1.6500 x 800 |
Day's Range | 1.4000 - 1.4550 |
52 Week Range | 1.1600 - 12.9500 |
Volume | |
Avg. Volume | 317,838 |
Market Cap | 61.815M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5770 |
Earnings Date | Mar 10, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.88 |
Subscribe to Yahoo Finance Plus to view Fair Value for GMTX
Even if it's not a huge purchase, we think it was good to see that Braden Leonard, a Gemini Therapeutics, Inc...
Remote-First-Company/Mass., March 10, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX) today reported financial results for the year ended December 31, 2021.
Remote-First-Company/Mass., February 28, 2022--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today provided a corporate update announcing a leadership transition, strategic evaluation and corporate restructuring.